Abstract. Background/Aim: This research was aimed to evaluate the association between three selected single nucleotide polymorphisms (SNPs) within the CDKN2A (P14ARF) tumour suppressor gene and the incidence of endometrial cancer (EC) in postmenopausal women. Patients and Methods: The study included 194 postmenopausal women; 144 with EC and 50 non-cancer controls. Genotypes in P14ARF rs3088440, rs3731217 and rs3731245 polymorphisms were assayed using PCR-RFLP and confirmed by sequencing. Results: Regarding the rs3088440 polymorphism, CT, and CT-TT genotypes, were more prevalent among EC patients than in controls (OR=5.55, p=0.023, OR=5.29, p=0.027; and OR=2.92, p=0.023, respectively). The T allele within rs3088440 was more prevalent in EC females (χ²=4.7, p=0.030). Considering rs3731217, TG and TG-GG genotypes were less prevalent among EC (OR=0.34, p=0.024 or p=0.023; and OR=0.38, p=0.035, respectively). Conclusion: Polymorphisms in the CDKN2A gene are associated with EC in postmenopausal women.

Endometrial cancer (EC) is the fourth most common cancer among Polish women (after breast, colon, and lung cancer) responsible for 3% of cancer deaths in this population. Moreover, the incidence rate of this cancer has almost doubled in the last three decades, due to several factors, especially the increased average life expectancy of women. Hence, EC is predominantly observed in postmenopausal women in their sixth/seventh decade of life, with the highest incidence rate of 80/100,000 at the end of the seventh decade (1).

P14ARF belongs to three tumour suppressor proteins, including p16INK4a and p15INK4b encoded by the CDKN2A gene, genetic changes of which may cause cellular proliferation and tumour growth (2, 3). It has been shown that p14ARF influenced the course of cell cycle by activating p53 and inhibiting MDM2 expression thus leading to cell cycle arrest in G1 and G2/M phases (4, 5). Altered expression of p14ARF, either decreased or increased, has been found in various human tumours (5-8). Considering EC, tumor heterogeneity in CDKN2A protein expression between four different cores of primary tumours, has been reported as significantly more prevalent among samples with a higher stage of the disease (9). In another study, CDKN2A tumour suppressor gene was included in a panel of seven immunohistochemical markers [ER, CDKN2A (p16), TP53, VIM, PTEN, PGR, and IGF2BP3] to differentiate endometrioid carcinoma in FIGO grade 3 from serous carcinoma, based on immunohistochemical qualitative assays performed by tissue microarrays (10). Moreover, moderate immunohistochemical expression of p14 has been observed in endometrioid endometrial carcinoma, while total lack has been found in endometrial hyperplasias without atypia, at the
Mutations in PTEN and KRAS, as well as microsatellite instability have, so far, been related to oestrogen-related, type I EC, while mutations in TP53, HER-2 and P16 have been associated with type II EC, unrelated to oestrogen (12).

So far, distinct single nucleotide polymorphisms (SNPs) in CDKN2A (P14ARF) have been correlated with various tumours, like acute lymphoblastic leukaemia (ALL), nasopharyngeal carcinoma, medullary thyroid carcinoma, oropharyngeal cancer, oesophageal squamous cell carcinoma (ESCC), or salivary gland carcinoma (13-18). The rs3088440 polymorphism, located in the 3' UTR region of CDKN2A, has been shown to be important in the susceptibility to and for the prognosis of several cancers, including HPV16-positive oropharynx cancer, melanoma, or squamous cell carcinoma of the head and neck (SCCHN) (14, 17, 19). Among patients with paediatric B-cell precursor ALL (BCP-ALL), rs3731217 SNP in intron 1 of CDKN2A, has been suggested to influence the risk of cancer, by regulating alternative splicing of CDKN2A, possibly associated with the translation of p16 and p14ARF tumour suppressors (Figure 1) (20). It is noteworthy that TGA/CAG diploptypes and TGA/TAG variants for rs3731217, rs3731245, and rs3088440 SNPs, have been proposed to possibly be associated with a decreased and an increased risk of chronic benzene poisoning, respectively (21). Our previous study, performed in postmenopausal women with EC, has shown the joint effect of MDM2 SNP309, TP53 SNP rs1042522, as well as of the three polymorphisms of P14ARF in the occurrence of the cancer (22). Based on the reported changes in the protein levels of p14ARF tumour suppressor, involved in EC, as well as previous research on the functional role of the three SNPs, rs3088440, rs3731217 or rs3731245, residing within P14ARF gene, a further study seems to be justified and needed regarding the contribution of the presented polymorphisms to EC. In that context, the goal of the current study was to evaluate the relationship between the three selected SNPs and the risk for EC in a population of postmenopausal women.

**Patients and Methods**

This retrospective study included 194 women; 144 with EC and 50 non-cancer control individuals (Table I). The females qualified for the study were patients of the Department of Gynaecology and Oncological Gynaecology at the Polish Mother’s Memorial Hospital – Research Institute in Lodz, between December 1997 and August 2009. The qualified women were between 28 and 88 years old (the mean age: 59.1 years). The ECs of the qualified patients were staged, according to the criteria of the International Federation of Gynaecology and Obstetrics (FIGO), and the tumour specimens were obtained by a dilatation and curettage (D&C) procedure, picking up some mucous membrane from the uterine cavity. Normal
Wujcicka et al.: SNPs in CDKN2A Tumour Suppressor Gene and Endometrial Cancer

Table I. Characteristics of the examined women with endometrial cancer and of non-cancer controls.

| Characteristics              | Females with endometrial cancer | Non-cancer controls | p-Value |
|------------------------------|----------------------------------|---------------------|---------|
| Examined women; n (%)        | 144 (74.2)                      | 50 (25.8)           |         |
| Mean age±SD (years)          | 61.24±9.01                      | 53.06±4.75          |         |
| Diabetes mellitus (%)        | 27/144 (19.0)                   | 0/48 (0.0)          | 0.001   |
| Arterial hypertension (%)    | 76/144 (52.8)                   | 16/48 (33.3)        | 0.020   |
| BMI                          |                                  |                     |         |
| Mean±SD (kg/m²)              | 30.25±6.25                      | 27.43±5.17          |         |
| ≥24.99 (%)                   | 30/137 (21.9)                   | 17/48 (35.4)        | 0.014   |
| 25-29.99 (%)                 | 40/137 (29.2)                   | 19/48 (39.6)        |         |
| ≥30 (%)                      | 67/137 (48.9)                   | 12/48 (25.0)        |         |
| MHT                          |                                  |                     |         |
| Yes (%)                      | 13/65 (20.0)                    | 9/47 (19.1)         | 0.911   |
| No (%)                       | 52/65 (80.0)                    | 38/47 (80.9)        |         |
| FIGO grade                   |                                  |                     |         |
| G1 (%)                       | 63/113 (55.8)                   |                     |         |
| G2 (%)                       | 46/113 (40.7)                   |                     |         |
| G3 (%)                       | 12/113 (10.6)                   |                     |         |
| FIGO stage                   |                                  |                     |         |
| I (%)                        | 86/131 (65.6)                   |                     |         |
| II (%)                       | 23/131 (17.6)                   |                     |         |
| III (%)                      | 22/131 (16.8)                   |                     |         |
| Endometrial thickness        |                                  |                     |         |
| Mean±SD (mm)                 | 14.64±13.02                     | 6.23±2.99           |         |
| >5 mm (%)                    | 107/127 (84.3)                  | 23/45 (51.1)        | 9×10⁻⁶  |

n: Number of examined women; SD: standard deviation; BMI: body mass index; MHT: menopausal hormone therapy; FIGO: the International Federation of Gynaecology and Obstetrics; Pearson’s Chi-squared test.

endometrial tissues of the non-cancer controls were used as control samples, obtained also by curettage, performed for medical indications (in patients with bleeding from the genital tract or prepared for gynaecological procedures). The study was approved (approval number: 2/2016) by the Research Ethics Committee at the Polish Mother’s Memorial Hospital - Research Institute. All the samples, previously collected for diagnostic purposes, were anonymised in the reported project. Informed consent forms were signed by the qualified women, the consent procedure had first been accepted by the Research Ethics Committee.

DNA extraction. Genomic DNA specimens were extracted from stored, paraffin-embedded sections of cancerous and healthy endometrial tissues, using a Syngen FFPE DNA Micro Kit (Syngen Biotech, Wroclaw, Poland). The obtained DNA was diluted in 100 μl elution buffer and stored at –20°C until further genetic analyses.

Genotyping of SNPs, located within CDKN2A (P14ARF) gene. The genotypes, of the polymorphisms rs3088440, rs3731217 and rs3731245 located within CDKN2A (P14ARF), were determined, using self-designed nested PCR-RFLP assays. The primer sequences and conditions of the PCR assays are presented in Table II. The external primers were designed, using the PerlPrimer v1.1.21 software, and the internal primers were obtained from the literature (15, 19, 22-24). Nested PCR products were resolved on 1% agarose gels, stained with ethidium bromide, and then digested overnight with HaeIII (EURx, Gdansk, Poland), and Mval (Thermo Fisher Scientific, Waltham, MA, USA) endonucleases to determine genotypes of rs3088440 and rs3731217, as well as of rs3731245 polymorphisms, respectively. Genotypic profiles were estimated from the length of the achieved restriction fragments, resolved on 2% agarose gels (Figure 2, Table III). Several specimens for rs3731217 (four EC cases) and rs3731245 (three ECs and one control case) polymorphisms were excluded from further analysis due to the lack of digested fragments, observed on agarose gels. The selected PCR products, representative of distinct genotypes in the studied SNPs, were then sequenced by the Sanger method at the Genomed Joint-Stock Company (Warsaw, Poland), to confirm nested PCR-RFLP outcomes. The sequencing process was performed for nine CC homozygotes, twelve CT heterozygotes and two TT homozygotes in rs3088440 SNP, for eleven TT homozygotes, and five TG heterozygotes in rs3731217 polymorphism, as well as for one GA heterozygote and fifteen GG homozygotes in rs3731245 polymorphism of the P14ARF gene. The sequences of obtained chromatograms were analysed by the Sequence Scanner 1.0 (Applied Biosystems, Waltham, MA, USA) program.

Statistical analysis. The distribution of obtained clinical data, as well as of single genotypes, alleles, and haplotypes was estimated by descriptive statistics, using the SPSS software (25). Genotypes in the analysed polymorphisms were determined by the Hardy-Weinberg (H-W) equilibrium and linkage disequilibrium (LD). Relationships were calculated between the clinical data and genotypes of the polymorphisms and the occurrence of EC among the examined women, using the cross-tabulation and the Pearson’s Chi-square test. A logistic regression model was employed to define the genetic models of inheritance, including codominant, dominant, recessive and overdominant. The undertaken attempts identified optimal inheritance models of the genetic changes of the studied polymorphisms, typical for EC in the examined patients. The multiple-SNP analyses of haplotypes in P14ARF SNPs were performed by the Expectation Maximization (EM) algorithm. The results were acknowledged as statistically significant at the significance level of p≤0.050. The statistical analysis was, in part, supported by the NCSS 2004 software.

Results

Hardy-Weinberg equilibrium, linkage disequilibrium. Hardy-Weinberg (H-W) equilibrium was preserved in CDKN2A (P14ARF) rs3731217 and rs3731245 polymorphisms in all of the examined female patients (p>0.050), while it was not found in rs3088440 SNP among the analyzed patients (p≤0.050). Polymorphisms were observed in the linkage disequilibrium (LD), found between the analyzed groups of women (p≤0.050).

Distribution of genotypes within CDKN2A (P14ARF) gene polymorphisms. In the females with endometrial cancer, the CC, CT and TT genotypes within P14ARF rs3088440 SNP...
were observed in 71.5% (103/144), 18.1% (26/144), and 10.4% (15/144), respectively (Table IV). In the case of rs3731217, the TT, TG and GG genotypes were found in 91.4% (128/140), 7.9% (11/140), and 0.7% (1/140) of the studied patients, respectively. Considering rs3731245, the GG homozygous status was observed in all the non-cancer females. Figure 3 illustrates examples of the chromatograms for the genotypes in the analysed P14ARF polymorphisms.

Considering the rs3088440 polymorphism, the CT heterozygous females were found to be significantly positively associated with EC, as compared to the CC and TT homozygous patients (OR=5.55, 95%CI=1.26-24.42, in the codominant model, \(p=0.023\), and OR=5.29, 95%CI=1.21-23.16, in the overdominant model, \(p=0.027\), Table IV). Moreover, the CT-TT genotypes were significantly more prevalent among the cancerous patients (OR=2.92, 95%CI=1.16-7.37, in the dominant model, \(p=0.023\)). In the case of rs3731217 SNP, the TG heterozygous status was significantly less prevalent among the patients with EC, as compared to TT-GG homozygotes (OR=0.34, 95%CI=0.14-0.87, in the codominant model, \(p=0.024\), and 95%CI=0.13-0.86, in the overdominant model, \(p=0.023\)). Furthermore, the dominant model showed that the TG-GG genotypes were significantly negatively associated with tumour occurrence (OR=0.38, 95%CI=0.15-0.93, \(p=0.035\)). Additionally, the multiple-SNP analysis showed significantly higher prevalence rates of the CTA haplotypes in the range of all the studied polymorphisms, observed among the females with EC, as compared to the non-cancer individuals (\(p≤0.050\)). Taking into account the clinical data of the studied patients, similar prevalence rates were observed for all the analyzed genotypes in the studied women.

Allelic variants within SNPs of the P14ARF gene. Among the females with endometrial cancer, the C and T alleles within rs3088440 SNP were found with prevalence rates of 81.0% (232/288) and 19.0% (56/288), respectively (Table V). In the case of rs3731217 polymorphism, the T and G alleles were observed with prevalence rates of 95.0% (267/280) and 5.0% (9/280), respectively. Regarding the rs3731245 polymorphism, the prevalence rates of G and A alleles were 97.0% (273/282) and 3.0% (9/282), respectively. In the non-cancer control women, the C and T alleles within rs3088440, and the T and G alleles in rs3731217 polymorphisms were determined with prevalence rates of 90.0% (90/100) and 10.0% (10/100), respectively. In the case of rs3731245, only the G allele was identified in all the studied control individuals (100.0%, 98/98). Regarding the rs3088440 polymorphism, the T allele was significantly more prevalent among the females with EC, as compared to the non-cancer control individuals (\(\chi^2=4.7, p=0.030\), Table V). In turn, the alleles in both rs3731217 and rs3731245 polymorphic sites were similarly distributed between the studied groups of women.

Discussion

Studies on correlations between p14ARF and endometrial cancer have, so far, been rather not numerous, while p14ARF is a component of the p53 pathway (p14ARF/MDM2/p53), essential for the development and progression of various in vivo 34: 943-951 (2020)

Table II. Conditions of nested PCR assays for genotyping of the polymorphisms located within CDKN2A (P14ARF) gene.

| GenBank Accession No. | SNP name [global MAF (%)] | Oligonucleotide sequences (5'-3') | Annealing temperature (˚C) | Amplicon length (bps) |
|-----------------------|---------------------------|-----------------------------------|-----------------------------|-----------------------|
| NC_000009.12          | rs3088440 (16.99)         | For: TGCTCACTCCAGAAAACCTCA       | 55                          | 356                   |
|                       |                           | Rev: ATGTGCCACACATCTTTGACC       |                             |                       |
| rs3731217             | rs3088440 (12.54)         | For: GATGTCACACACATCTTTGACC      | 55                          | 181                   |
|                       |                           | Rev: CTACGAAACGGGTTGGGTTTGTG     |                             |                       |
| rs3731245             | rs3088440 (4.97)          | For: CAGGTGAAGAATGTGATTTGG       | 55                          | 590                   |
|                       |                           | Rev: CAAGTTGAAGTGTTCAATTGGAG     |                             |                       |
|                       | rs3731217 (12.54)         | For: AAAAGGTCACACATTCC           | 55                          | 280                   |
|                       |                           | Rev: CCCCTCTCAAAATATGCTGTCC      |                             |                       |
|                       | rs3731245 (4.97)          | For: ACTCTCAATTCAAAACCTGGG       | 55                          | 440                   |
|                       |                           | Rev: CCAAATCTATGTCTATATCTCTC     |                             |                       |

No.: Number; SNP: single nucleotide polymorphism; MAF: minor allele frequency; bps: base pairs.
human neoplasms, including EC (4, 5, 22). Certain modulations in EC cells kinetics, possible via alterations in this pathway, [p14ARF/p53/p21(WAF1)], may result from a correlation between Sox9 and NF-κB signalling mechanisms, as well as from the Akt status (26). Olcha et al. have observed expression of p14ARF protein in more than a half of the analyzed primary EC and metastatic lesions and found it to be positively associated with the transtubal dissemination of the primary tumour (27). Expression of p14ARF has been found by Watanabe et al. to be significantly higher in G1 EC tumours than in normal endometrial hyperplasias (5).

In the current study, the CT heterozygotes, as compared to CC and TT homozygotes, as well as the CT-TT genotypes, in the P14ARF rs3088440 SNP were found to be significantly more prevalent among the EC patients than in the controls. Moreover, the T allele, present within rs3088440 region, was significantly associated with the cancer phenotype. The GA and AA genotypes within the rs3088440 SNP, have been previously assumed to be correlated with an increased risk of second primary malignancy among patients with SCCHN as well (19). In another study, the T allele within rs3088440 has been reported to be correlated with an increased risk of melanoma (28). Considering the role of rs3088440, the C allele has been reported to favour the binding of c-Myb transcription factor to the transcriptional regulatory region of CDKN2A, possibly resulting in its repression and compromise of its normal function in cell cycle (16, 29). In turn, the A allele has been found to be possibly associated with an impaired binding of miR-663b to the CDKN2A 3’ UTR, leading to an increased expression of p14/p16 proteins (14, 30). Therefore, the contribution of the T allele to EC formation seems fairly plausible through the altered binding of transcription factors to the transcriptional regulatory site of CDKN2A.

In case of rs3731217 SNP, TG heterozygotes, as well as the TG-GG genotypes, were found to be significantly less

### Table III. Restriction endonucleases and genotypic profiles obtained in PCR-RFLP assays.

| Polymorphism | Restriction enzyme | Profile (bps) |
|--------------|--------------------|--------------|
| rs3088440    | HaeIII             | CC: 142, 39  |
|              |                    | CT: 181, 142, 39 |
|              |                    | TT: 181      |
| rs3731217    | MvaI               | TT: 280      |
|              |                    | TG: 280, 154, 126 |
|              |                    | GG: 154, 126 |
| rs3731245    | HaeIII             | AG: 195, 123, 72 |
|              |                    | GG: 123, 72  |

bps: Base pairs.
prevalent among the EC patients as compared to the controls. The rs3731217 polymorphism has been previously associated with ALL in the Caucasians, and the minor G allele within the SNP was found to be protective against paediatric BCP-ALL (18, 31). In turn, the incidence rates of the T allele have been found to be similar, both among cases and controls for paediatric ALL in the Tunisian population (32). Among patients with HPV16-positive squamous cell carcinoma of the oropharynx (SCCOP), the carriers of the TT genotype have been reported to have an increased risk either for death or for the recurrence of the disease, as compared to TG or GG genotypes (17). Regarding the functional analysis of rs3731217, the minor G allele has been associated with an elevated expression of exon 3, encompassing the 3’-UTR of CDKN2A, resulting in higher levels of CDKN2A tumour suppressor protein (20). In the case of EC, the G allele of the rs3731217 polymorphic site seemed also to be protective against the cancer.

Regarding rs3731245, the polymorphism has previously been reported to be associated with cerebral infarction, a risk of chronic benzene poisoning and with the ischemic stroke subtype-small vessel disease (21, 33, 34). Considering the functional significance of rs3731245, located within the first intron of CDKN2A gene, it has been suggested to possibly be either in LD with other functional SNPs in the genomic region of CDKN2A or in LD with an intron-based transcription enhancer or silencer, located in the first intron

### Table IV. Relationships between genotypes in P14ARF single nucleotide polymorphisms and the occurrence of endometrial cancer in the patients.

| Gene polymorphism | Genetic model | Genotype | Endometrial cancer | Control individuals | OR (95%CI)       | p-Value |
|-------------------|---------------|----------|--------------------|---------------------|------------------|---------|
| rs3088440         | Codominant    | CC       | 103 (71.5%)        | 44 (88.0%)          | 1.00             | 0.023   |
|                   |               | CT       | 26 (18.1%)         | 2 (4.0%)            | 5.55 (1.26-24.42)| 0.023   |
|                   |               | TT       | 15 (10.4%)         | 4 (8.0%)            | 1.60 (0.50-5.10) | 0.425   |
|                   | Dominant      | CC       | 103 (71.5%)        | 44 (88.0%)          | 1.00             |         |
|                   |               | CT-TT    | 41 (28.5%)         | 6 (12.0%)           | 2.92 (1.16-7.37) | 0.023   |
|                   | Recessive     | CC-CT    | 129 (89.6%)        | 46 (92.0%)          | 1.00             |         |
|                   |               | TT       | 15 (10.4%)         | 4 (8.0%)            | 1.34 (0.42-4.24) | 0.621   |
|                   | Overdominant  | CC-TT    | 118 (81.9%)        | 48 (96.0%)          | 1.00             |         |
|                   |               | CT       | 26 (18.1%)         | 2 (4.0%)            | 5.29 (1.21-23.16)| 0.027   |
| rs3731217         | Codominant    | TT       | 128 (91.4%)        | 40 (80.0%)          | 1.00             |         |
|                   |               | TG       | 11 (7.9%)          | 10 (20.0%)          | 0.34 (0.14-0.87) | 0.035   |
|                   |               | GG       | 1 (0.7%)           | 0 (0.0%)            | NA (0.00-NA)     | 0.024   |
|                   | Dominant      | TT       | 128 (91.4%)        | 40 (80.0%)          | 1.00             |         |
|                   |               | TG-GG    | 12 (8.6%)          | 10 (20.0%)          | 0.38 (0.13-0.86) | 0.023   |
|                   | Recessive     | TT-TG    | 139 (99.3%)        | 50 (100.0%)         | 1.00             |         |
|                   | Overdominant  | TT-GG    | 129 (92.1%)        | 40 (80.0%)          | 1.00             |         |
|                   |               | TG       | 11 (7.9%)          | 10 (20.0%)          | 0.34 (0.13-0.86) | 0.023   |
| rs3731245         | Codominant    | -        | 132 (93.6%)        | 49 (100.0%)         | 1.00             |         |
|                   |               | GG       | 132 (93.6%)        | 49 (100.0%)         | 1.00             |         |
|                   |               | GA       | 9 (6.4%)           | 0 (0.0%)            | NA (0.00-NA)     |         |

n: Number of tested women; OR: odds ratio; 95% CI: confidence interval; logistic regression model; NA: not analyzed.

### Table V. Distribution of alleles in P14ARF polymorphisms.

| Gene polymorphism and alleles | Females with endometrial cancer | Controls | p-Value |
|------------------------------|--------------------------------|----------|---------|
| rs3088440 C                  | 232 (81.0)                     | 90 (90.0) | 0.030   |
| rs3088440 T                  | 56 (19.0)                      | 10 (10.0) |         |
| rs3731217 T                  | 267 (95.0)                     | 90 (90.0) | 0.054   |
| rs3731217 G                  | 13 (5.0)                       | 10 (10.0) |         |
| rs3731245 G                  | 273 (97.0%)                    | 98 (100.0%) | 0.073   |
| rs3731245 A                  | 9 (3.0%)                       | 0 (0.0%)  |         |

No.: Number; Pearson’s Chi-squared test.
Summing up, three CDKN2A polymorphisms, studied in the current research project, were plausibly associated with the occurrence of EC among the postmenopausal women. Considering its functional analysis, the minor T allele within rs3088440 may have contributed to the cancer formation through an altered binding of transcription factors to the CDKN2A 3’ UTR region, while the minor G allele within rs3731217 seemed to be protective against EC. The important positive relationship between the CTA haplotypes, observed for all the studied CDKN2A SNPs and EC, may be also suggestive of rs3731245 association with the cancer.

Taking into account our previous studies, we demonstrated that the SNP309 polymorphism of the MDM2 gene is strongly associated with EC (both the GG genotype and the G allele), while the TP53 codon 72 polymorphism has been of a prognostic value and useful for the prophylaxis from EC (the Arg/Arg homozygote has been linked with an increased, while the Pro/Arg heterozygote and the Pro allele - with a decreased EC risk) (35-37). Moreover, the research about the joint effect of MDM2 SNP309, TP53 rs1042522, and the three currently described P14ARF polymorphisms on the onset of EC in postmenopausal women, concluded that MDM2 SNP309 plays a role in this cancer (22). The multiple-SNP combinations G-Arg-C-T-G for MDM2, TP53, and the three P14ARF polymorphisms increased EC risk, while the T-Arg-C-T-G variants decreased risk for disease (22). Further studies seem to be justified and needed to reveal the detailed role of P14ARF SNPs in endometrial cancer formation.
Conflicts of Interest

The Authors have no conflicts of interest to disclose regarding this study.

Authors’ Contributions

Wioletta Wucicicka: Design and performance of genetic research, data collection and management, data analysis and interpretation, manuscript writing and editing, final approval of the submitted version of manuscript; Agnieszka Zającz: Conception, data collection, revising the article, final approval of the submitted version of manuscript; Krysztof Syzczylo: Data collection and management, final approval of the submitted version of manuscript; Beata Smolarz: Data collection and management, final approval of the submitted version of manuscript; Hanna Romanowicz: Data collection and management, final approval of the submitted version of manuscript; Grzegorz Stachowiak: Project development, data collection and management, interpretation of data, manuscript writing and editing, final approval of the submitted version of manuscript.

Acknowledgements

This study was funded by the Polish Ministry of Science & Higher Education and by Polish Mother’s Memorial Hospital-Research Institute (Grant No. 2016/VII/30-GW).

References

1. Endometrial Neoplasms (C54). Available at: http://onkologia.org.pl/nowotwory-trzonu-macicy-kobiet-c54/[Last accessed 16/01/2020]
2. El-Mokadem I, Kidd T, Pratt N, Fleming S and Nabi G: Tumour suppressor gene (CDKN2A) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer. Oncotarget 7(45): 73045-73054, 2016. PMID: 27682877. DOI: 10.18632/oncotarget.12196
3. Ioane K and Fry EA: Aberrant expression of p14(ARF) in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol 29(6): 212-214, 2017. PMID: 28509323. DOI: 10.5603/GP.a2017.0040
4. Gu F, Pfeiffer RM, Bhattacharjee S, Han SS, Taylor PR, Berndt S, Yang H, Sigurdson AJ, Toro J, Mirabello L, Greene MH, Freedman ND, Abnet CC, Dawsey SM, Hu N, Qiao YL, Ding T, Brenner AV, Garcia-Closas M, Hayes R, Brinton LA, Lissowska J, Wentzensen N, Kratz C, Moore LE, Ziegler RG, Chow WH, Savage SA, Burdette L, Yanger M, Chanock SJ, Chatterjee N, Tucker MA, Goldstein AM and Yang XR: Common genetic variants in the 9p21 region and their associations with multiple tumours. Br J Cancer 108(6): 1378-1386, 2013. PMID: 23361049. DOI: 10.1038/bjc.2013.7
5. Guo C, Huang Y, Yu J, Liu G, Gong X, Huang M, Jiang C, Liao Y, Huang L, Yang G and Li J: The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget 8(15): 25334-25344, 2017. PMID: 28445979. DOI: 10.18632/oncotarget.15835
6. Jin L, Xu L, Song X, Wei Q, Sturgis EM and Li G: Genetic variation in MDM2 and p14ARF and susceptibility to salivary gland carcinoma. PLoS One 7(11): e49361, 2012. PMID: 23145162. DOI: 10.1371/journal.pone.0049361
7. Nascimento FP, Cardoso MG, Lindsey SC, Kunii IS, Valente FO, Kizys MM, Delcelo R, Camacho CP, Maciel RM and Dias-Da-Silva MR: Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma. Mol Med Rep 7(4): 613-619, 2014. PMID: 25048628. DOI: 10.1016/j.tranon.2014.06.001
8. Zhou X, Liao F, Zhang J, Qin Y, Xu H, Ding Z, Zhang Y and Zhang F: Association of the independent polymorphisms in CDKN2A with potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy. Carcinogenesis 35(1): 62-68, 2014. PMID: 24104554. DOI: 10.1093/carcin/bgt336
9. Zhou X, Liao F, Zhang J, Qin Y, Xu H, Ding Z, Zhang Y and Zhang F: Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia. Biosci Rep 38(3), 2018. PMID: 29654170. DOI: 10.1042/BSR20180331
10. Zhang Y, Sturgis EM, Zafereo ME, Wei Q and Li G: p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer 117(6): 1227-1235, 2011. PMID: 21381012. DOI: 10.1002/cncr.25605
20 Hungate EA, Vora SR, Gamazon ER, Moriyama T, Best T, Hulur I, Lee Y, Evans TJ, Ellinghaus E, Stanuila M, Rudant J, Orsi L, Clavel J, Milne E, Scott RJ, Pui CH, Cox NJ, Loh ML, Yang JJ, Skol AD and Onel K: A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat Commun 7: 10635, 2016. PMID: 26868379. DOI: 10.1038/ncomms10635
21 Sun P, Zhang Z, Wan J, Zhao N, Jin X and Xia Z: Association of genetic polymorphisms in GADD45A, MDM2, and p14 ARF with the risk of chronic benzene poisoning in a Chinese occupational population. Toxicol Appl Pharmacol 240(1): 66-72, 2009. PMID: 19596022. DOI: 10.1016/j.taap.2009.07.003
22 Wujcicka W, Zając A and Stachowiak G: Impact of MDM2, TP53 and p14ARF polymorphisms on endometrial cancer risk and onset. In Vivo 33(3): 917-924, 2019. PMID: 31028217. DOI: 10.21873/invivo.11559
23 Thakur N, Hussain S, Nasare V, Das BC, Basir SF and Bharadwaj M: Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep 39(1): 407-414, 2012. PMID: 21567202. DOI: 10.1007/s12033-011-0752-z
24 Yan L, Na W, Shan K, Xiao-Wei M, Wei G and Shu-Cheng C: Thakur N, Hussain S, Nasare V, Das BC, Basir SF and Bharadwaj M: Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep 39(1): 407-414, 2012. PMID: 21567202. DOI: 10.1007/s12033-011-0752-z
25 SNPStats Software. Available at: https://www.snpstats.net/start.htm [Last accessed 16/01/2020]
26 Saegusa M, Hashimura M, Suzuki E, Yoshida T and Kuwata T: SNPStats Software. Available at: https://www.snpstats.net/start.htm [Last accessed 16/01/2020]
27 Olcha P, Cybulski M, Skomra D, Obrzut B, Ignatov A, Jóźwik M, Schneider-Stock R and Semczuk A: The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations. Int J Gynecol Cancer 20(6): 993-999, 2010. PMID: 20683407. DOI: 10.1111/j.1525-1438.2009.00953.x
28 Maccioni L, Rachakonda PS, Bermejo JL, Planelles D, Requena C, Hemminki K, Nagore E and Kumar R: Variants at the 9p21 locus and melanoma risk. BMC Cancer 13: 325, 2013. PMID: 23816148. DOI: 10.1186/1471-2407-13-325
29 Stennan G, Andersson MK and Andren Y: New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle 9(15): 2986-2995, 2010. PMID: 20647765. DOI: 10.4161/cc.9.15.12515
30 Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whitman DC, Wu AH, Reid BJ and Vaughan TL: Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis 35(12): 2740-2747, 2014. PMID: 25280564. DOI: 10.1093/carcin/bgu207
31 Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Seneafi AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Gonzalez Neira A, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M and Houlston RS: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 42(6): 492-494, 2010. PMID: 20453839. DOI: 10.1038/ng.585
32 Gharbi H, Ben H, I, Soltani I, Safra I, Ouerhani S, Bel Haj Othmen H, Teber M, Farah A, Amouri H, Toumi NH, Abdennabi S, Abbas S and Menif S: Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence. Pediatr Hematol Oncol 33(3): 157-167, 2016. PMID: 27184773. DOI: 10.3109/08880018.2016.1161865
33 Hu WL, Li SJ, Liu DT, Wang Y, Niu SQ, Yang XC, Zhang Q, Yu SJ, Jin L and Wang XF: Genetic variants on chromosome 9p21 and ischemic stroke in Chinese. Brain Res Bull 79(6): 431-435, 2009. PMID: 19559344. DOI: 10.1016/j.brainresbull.2009.04.001
34 Yue X, Tian L, Fan X, Xu G, Shi FD and Liu X: Chromosome 9p21.3 variants are associated with cerebral infarction in Chinese population. J Mol Neurosci 56(3): 546-552, 2015. PMID: 25665551. DOI: 10.1007/s12031-015-0494-9
35 Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J and Smolarz B: Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol 63(4): 278-283, 2012. PMID: 23359199. DOI: 10.5114/pjp.2012.32776
36 Zając A, Stachowiak G, Smolarz B and Wilczyński JR: Chromosome 9p21 and ischemic stroke in Chinese. Brain Res Bull 79(6): 431-435, 2009. PMID: 19559344. DOI: 10.1016/j.brainresbull.2009.04.001
37 Zając A, Smolarz B, Stachowiak G and Wilczyński JR: Polymorphisms of codon 72 of the TP53 gene in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway. Am J Pathol 181(2): 684-692, 2012. PMID: 22699886. DOI: 10.1016/j.ajpath.2012.05.008
38 Clavel J, Milne E, Scott RJ, Pui CH, Cox NJ, Loh ML, Yang JJ, Skol AD and Onel K: A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat Commun 7: 10635, 2016. PMID: 26868379. DOI: 10.1038/ncomms10635
39 Yu SZ, Jin L and Wang XF: Genetic variants on chromosome 9p21 and ischemic stroke in Chinese. Brain Res Bull 79(6): 431-435, 2009. PMID: 19559344. DOI: 10.1016/j.brainresbull.2009.04.001
40 Yue X, Tian L, Fan X, Xu G, Shi FD and Liu X: Chromosome 9p21.3 variants are associated with cerebral infarction in Chinese population. J Mol Neurosci 56(3): 546-552, 2015. PMID: 25665551. DOI: 10.1007/s12031-015-0494-9
41 Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J and Smolarz B: Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol 63(4): 278-283, 2012. PMID: 23359199. DOI: 10.5114/pjp.2012.32776
42 Zając A, Stachowiak G, Smolarz B and Wilczyński JR: Polymorphisms of codon 72 of the TP53 gene in endometrial carcinoma of postmenopausal women. Postepy Hig Med Dosw (Online) 67: 1312-1318, 2013. PMID: 24379271. DOI: 10.5604/17322693.1080804
43 Zając A, Smolarz B, Stachowiak G and Wilczyński JR: TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. Med Oncol 31(11): 286, 2014. PMID: 25316267. DOI: 10.1007/s12032-014-0286-z

Received December 28, 2019
Revised January 14, 2020
Accepted January 16, 2020